Abstract
This article examines prostate cancer as a target for immunotherapy and investigates active immunotherapy for prostate cancer, combining conventional therapy with active immunotherapy, immune modulators (brakes and accelerators), and monoclonal antibodies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 121-129 |
| Number of pages | 9 |
| Journal | Urologic Clinics of North America |
| Volume | 37 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 2010 |
Fingerprint
Keywords
- CTLA4
- Lymphocyte
- PD-1
- Prostate cancer
- T cell
- Vaccine
ASJC Scopus subject areas
- Urology
Cite this
Immunotherapy for Prostate Cancer : An Emerging Treatment Modality. / Drake, Charles G.
In: Urologic Clinics of North America, Vol. 37, No. 1, 02.2010, p. 121-129.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Immunotherapy for Prostate Cancer
T2 - An Emerging Treatment Modality
AU - Drake, Charles G.
PY - 2010/2
Y1 - 2010/2
N2 - This article examines prostate cancer as a target for immunotherapy and investigates active immunotherapy for prostate cancer, combining conventional therapy with active immunotherapy, immune modulators (brakes and accelerators), and monoclonal antibodies.
AB - This article examines prostate cancer as a target for immunotherapy and investigates active immunotherapy for prostate cancer, combining conventional therapy with active immunotherapy, immune modulators (brakes and accelerators), and monoclonal antibodies.
KW - CTLA4
KW - Lymphocyte
KW - PD-1
KW - Prostate cancer
KW - T cell
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=75349096325&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=75349096325&partnerID=8YFLogxK
U2 - 10.1016/j.ucl.2009.11.001
DO - 10.1016/j.ucl.2009.11.001
M3 - Article
C2 - 20152525
AN - SCOPUS:75349096325
VL - 37
SP - 121
EP - 129
JO - Urologic Clinics of North America
JF - Urologic Clinics of North America
SN - 0094-0143
IS - 1
ER -